Samsung Bioepis is embarking on collaboration with global pharmaceutical company Teva on the development and commercialization of two biosimilar candidates for immune disease treatments.

Samsung Bioepis announced on the 1st that it has signed a partnership agreement with Teva Pharmaceutical Industries for Fasenra biosimilar “SB41” and Ilaris biosimilar “SB44.”

Fasenra is an immune disease treatment with the active ingredient benralizumab, and Ilaris is a treatment with the active ingredient canakinumab.

Under the agreement, Samsung Bioepis will be responsible for the development, regulatory approval, and manufacturing of SB41 and SB44. Teva will handle sales in the United States, Europe, and Canada.

The two companies also agreed on an option to expand the partnership to include additional sales territories and collaboration on subsequent biosimilar development. Specific contract amounts and terms were not disclosed.

Samsung Bioepis and Teva have maintained an existing collaborative relationship. Last year, they launched the rare disease treatment “Epiuscly” in the United States, and more recently, they entered into a sales partnership in Canada for the ophthalmic disease treatment “Opuviz.”

Kim Kyung-ah, President and CEO of Samsung Bioepis, said, “Based on the achievements of our partnership with Teva, we have proceeded with collaboration on two new biosimilar candidates,” adding, “We will strengthen our pipeline across various disease areas and expand the supply of biosimilars.”

Samsung Bioepis is currently marketing 11 products in the global market. With the addition of SB41 and SB44 to the seven follow-on biosimilar pipeline candidates previously disclosed, the company’s follow-on biosimilar pipeline has expanded to a total of nine products.

Popular News